Olema Pharmaceuticals
Small molecule therapies targeting estrogen receptor signaling for metastatic breast cancer treatment
- Sector
- Biotech
- Headquarters
- SAN FRANCISCO, CA
- Latest Form D
- $250M, Dec 2024
- Total capital
- $503M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $503M
- 5 Form D · last Dec 2024
- 22 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 6
- 34 pending · first 2015
- Rank in peer group#245 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$250M
- Private capital raisedForm D · SEC · 4th filing$130M
- Private capital raisedForm D · SEC · 3rd filing$87.4M
- Private capital raisedForm D · SEC · 2nd filing$30M
- Private capital raisedForm D · SEC · 1st filing$6.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#245 · top 17%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Andrei ManoliuDirectorNamed in SEC Form D filings
- Andrew RappaportDirectorNamed in SEC Form D filings
- Cynthia ButittaDirectorNamed in SEC Form D filings
- Cyrus HarmonExecutive Officer, DirectorNamed in SEC Form D filings
- Cyrus L. Harmon, Ph.D.DirectorNamed in SEC Form D filings
- David MylesExecutive OfficerNamed in SEC Form D filings
Show all 28 people
- David C. Myles, Ph.D.Executive OfficerNamed in SEC Form D filings
- Frank McCormickDirectorNamed in SEC Form D filings
- Gorjan HrustanovicDirectorNamed in SEC Form D filings
- Gorjan HrustanovichDirectorNamed in SEC Form D filings
- Gorjan L. Hrustanovic, Ph.D.DirectorNamed in SEC Form D filings
- Graham WalmsleyDirectorNamed in SEC Form D filings
- Graham L. Walmsley, M.D., Ph.D.DirectorNamed in SEC Form D filings
- Ian L. ClarkDirectorNamed in SEC Form D filings
- John MoriartyExecutive OfficerNamed in SEC Form D filings
- Kinney HornExecutive OfficerNamed in SEC Form D filings
- Lawrence FritzDirectorNamed in SEC Form D filings
- Marina BozilenkoDirectorNamed in SEC Form D filings
- Naseem C. Zojwalla, M.D.Executive OfficerNamed in SEC Form D filings
- Pamela KleinExecutive OfficerNamed in SEC Form D filings
- Peter KusherExecutive Officer, DirectorNamed in SEC Form D filings
- Peter KushnerExecutive OfficerNamed in SEC Form D filings
- Sandra L. Horning, M.D.DirectorNamed in SEC Form D filings
- Scott L. GarlandDirectorNamed in SEC Form D filings
- Sean BohenExecutive Officer, DirectorNamed in SEC Form D filings
- Sean Bohen, M.D., Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
- Shane C. KovacsExecutive OfficerNamed in SEC Form D filings
- Yi C. LarsonDirectorNamed in SEC Form D filings
What it has protected
USPTO · 6 granted of 40- PendingRegimens Of Estrogen Receptor AntagonistsUSPTOApplication 19282664
- PendingEstrogen Receptor Modulators And Uses ThereofUSPTOApplication 19104880
- Pending2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE Derivatives As Estrogen Receptor Modulators For The Treatment Of CancerUSPTOApplication 19104872
Show all 40 patent records
- Regimens Of Estrogen Receptor AntagonistsMay 28, 2026 · Application 19282664Pending
- Estrogen Receptor Modulators And Uses ThereofApr 16, 2026 · Application 19104880Pending
- 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE Derivatives As Estrogen Receptor Modulators For The Treatment Of CancerFeb 26, 2026 · Application 19104872Pending
- Regimens Of Estrogen Receptor AntagonistsJul 29, 2025 · US 12,370,181Granted
- Salts And Solid Forms Of An Estrogen Receptor AntagonistJul 3, 2025 · Application 18867291Pending
- Fused Benzoisoxazolyl Compounds As KAT6A InhibitorsFeb 20, 2025 · Application 18718391Pending
- Methods Of Treating Estrogen Receptor-associated DiseasesFeb 13, 2025 · Application 18576880Pending
- TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGSApr 25, 2024 · Application 18142068Pending
- TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGSJun 13, 2023 · US 11,672,785Granted
- Compositions And Methods For Regulating Immune System ActivityMay 25, 2023 · Application 16486099Pending
- Methods Of Treating Estrogen Receptor-associated DiseasesApr 27, 2023 · Application 17908941Pending
- TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGSJan 25, 2022 · US 11,229,630Granted
- TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGSApr 21, 2020 · US 10,624,878Granted
- TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGSMay 21, 2019 · US 10,292,971Granted
- Novel Benzopyran Compounds, Compositions And Uses ThereofJul 16, 2015 · Application 14660248Pending
- Novel Benzopyran Compounds, Compositions and Uses ThereofApr 28, 2015 · US 9,018,244Granted
- Salts And Solid Forms Of Estrogen Receptor AntagonistApplication PCTUS2023022983Pending
- Dosage Forms Of An Estrogen Receptor AntagonistApplication 63431515Pending
- Dosage Forms Of An Estrogen Receptor AntagonistApplication 19136940Pending
- Methods Of Treating CancerApplication 63795155Pending
- 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE Derivatives As Estrogen Receptor Modulators For The Treatment Of CancerApplication 19104887Pending
- Methods Of Treating CancerApplication 63746217Pending
- Methods Of Treating Estrogen Receptor-associated DiseasesApplication PCTUS2022050213Pending
- Methods Of Treating Estrogen Receptor-mediated DisordersApplication PCTUS2022045774Pending
- Estrogen Receptor Modulators And Uses ThereofApplication 63399273Pending
- Estrogen Receptor Modulators And Uses ThereofApplication 63399269Pending
- Estrogen Receptor Modulators And Uses ThereofApplication 63399276Pending
- Methods Of Treating Estrogen Receptor-associated DiseasesApplication PCTUS2022036351Pending
- Methods Of Treating Estrogen Receptor Mediated DiseasesApplication 63284553Pending
- Methods Of Treating Estrogen Receptor-associated DiseasesApplication 63280860Pending
- Methods Of Treating Estrogen Receptor-associated DiseasesApplication 63278526Pending
- Methods Of Treating Estrogen Receptor Mediated DiseasesApplication 63252857Pending
- Methods Of Treating Estrogen Receptor-associated DiseasesApplication 63219802Pending
- Methods Of Treating Estrogen Receptor-associated DiseasesApplication PCTUS2021021151Pending
- Regimens Of Estrogen Receptor AntagonistsApplication PCTUS2020040863Pending
- Methods Of Treating Estrogen Receptor-associated DiseasesApplication 62985929Pending
- Regimens Of Estrogen Receptor AntagonistsApplication 62871592Pending
- Regimens Of Estrogen Receptor AntagonistsApplication 62871191Pending
- Compositions And Methods For Regulating Immune System ActivityApplication PCTUS2018019579Pending
- Compositions And Methods For Regulating Immune System ActivityApplication 62462725Pending
Related companies, and why
- Caradon Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- NEUTROLIS, INC.Similar federal contract value in Biotech · null in contracts
- Castle Creek Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- Veltion Therapeutics LLCSimilar federal contract value in Biotech · null in contracts
- Corridor Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Processa Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .